Evidence map›Paper›PMID 36572991›Full record

ArticleCancer2023

CCNE1 and survival of patients with tubo-ovarian high-grade serous carcinoma: An Ovarian Tumor Tissue Analysis consortium study.

Eun-Young Kang, Ashley Weir, Nicola S Meagher, Kyo Farrington, Gregg S Nelson, Prafull Ghatage, Cheng-Han Lee, Marjorie J Riggan, Adelyn Bolithon, Gordana Popovic and 138 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.

0numbers the graph read from it
0cells of the map it votes in
35citing papers in PubMed
6.6field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

35 citing papers in PubMed, 39 citations in OpenAlex.

  1. Trial
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Frontiers in cell and developmental biology · 2026
    Article
  11. Article
  12. Article
  13. Review
  14. Observational
  15. Article
  16. Article
  17. JCO precision oncology · 2025
    Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

148 authors at 20 institutions in 14 countries.

Eun-Young KangDepartment of Pathology and Laboratory Medicine, University of Calgary, Foothills Medical Center, Calgary, Alberta, Canada.
Ashley WeirSchool of Clinical Medicine, UNSW Medicine and Health, University of NSW Sydney, Sydney, New South Wales, Australia.
Nicola S MeagherSchool of Clinical Medicine, UNSW Medicine and Health, University of NSW Sydney, Sydney, New South Wales, Australia.ORCID 0000-0001-9134-2118
Kyo FarringtonDepartment of Pathology and Laboratory Medicine, University of Calgary, Foothills Medical Center, Calgary, Alberta, Canada.
Gregg S NelsonDepartment of Oncology, Division of Gynecologic Oncology, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.
Prafull GhatageDepartment of Oncology, Division of Gynecologic Oncology, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.
Cheng-Han LeeDepartment of Pathology and Laboratory Medicine, University of Alberta, Edmonton, Alberta, Canada.ORCID 0000-0003-2094-1222
Marjorie J RigganDepartment of Obstetrics and Gynecology, Division of Gynecologic Oncology, Duke University Medical Center, Durham, North Carolina, USA.
Adelyn BolithonAdult Cancer Program, Lowy Cancer Research Centre, University of NSW Sydney, Sydney, New South Wales, Australia.
Gordana PopovicStats Central, Mark Wainwright Analytical Centre, University of NSW Sydney, Sydney, New South Wales, Australia.
Betty LeungPrince of Wales Clinical School, UNSW Medicine and Health, University of NSW Sydney, Sydney, New South Wales, Australia.
Katrina TangDepartment of Anatomical Pathology, Prince of Wales Hospital, Sydney, New South Wales, Australia.
Neil LambieCanterbury Health Laboratories, Christchurch, New Zealand.
Joshua MillsteinDivision of Biostatistics, Department of Population and Public Health Sciences, Keck School of Medicine, University of Southern California, Los Angeles, California, USA.
Jennifer AlsopDepartment of Oncology, Centre for Cancer Genetic Epidemiology, University of Cambridge, Cambridge, UK.
Michael S AnglesioDepartment of Obstetrics and Gynecology, University of British Columbia, Vancouver, British Columbia, Canada.
Beyhan AtasevenDepartment of Gynecology and Gynecologic Oncology, Evangelische Kliniken Essen-Mitte (KEM), Essen, Germany.
Ellen BarlowGynaecological Cancer Centre, Royal Hospital for Women, Sydney, New South Wales, Australia.
Matthias W BeckmannDepartment of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, University Hospital Erlangen, Erlangen, Germany.
Jessica BergerDivision of Gynecologic Oncology, Department of Obstetrics, Gynecology and Reproductive Sciences, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
Christiani BisinottoDepartment of Gynecology and Obstetrics, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, Brazil.
Hans BösmüllerInstitute of Pathology and Neuropathology, Tuebingen University Hospital, Tuebingen, Germany.
Jessica BorosCentre for Cancer Research, The Westmead Institute for Medical Research, University of Sydney, Sydney, New South Wales, Australia.
Alison H BrandDepartment of Gynaecological Oncology, Westmead Hospital, Sydney, New South Wales, Australia.
Angela Brooks-WilsonCanada's Michael Smith Genome Sciences Centre, BC Cancer, Vancouver, British Columbia, Canada.
Sara Y BruckerDepartment of Women's Health, Tuebingen University Hospital, Tuebingen, Germany.
Michael E CarneyDepartment of Obstetrics and Gynecology, John A. Burns School of Medicine, University of Hawaii, Honolulu, Hawaii, USA.
Yovanni CasablancaUniformed Services of the Health Sciences Gynecologic Cancer Center of Excellence, Bethesda, Maryland, USA.
Alicia Cazorla-JiménezPathology Department, Fundación Jiménez Díaz, Madrid, Spain.
Paul A CohenDepartment of Gynaecological Oncology, St John of God Subiaco Hospital, Subiaco, Western Australia, Australia.
Thomas P ConradsWomen's Health Integrated Research Center, Inova Health System, Falls Church, Virginia, USA.
Linda S CookEpidemiology, School of Public Health, University of Colorado, Aurora, Colorado, USA.
Penny CoulsonDivision of Genetics and Epidemiology, The Institute of Cancer Research, London, UK.
Madeleine Courtney-BrooksDivision of Gynecologic Oncology, Department of Obstetrics, Gynecology and Reproductive Sciences, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
Daniel W CramerObstetrics and Gynecology Epidemiology Center, Department of Obstetrics and Gynecology, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA.
Philip CrowePrince of Wales Clinical School, UNSW Medicine and Health, University of NSW Sydney, Sydney, New South Wales, Australia.
Julie M CunninghamDepartment of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA.
Cezary CybulskiDepartment of Genetics and Pathology, International Hereditary Cancer Center, Pomeranian Medical University, Szczecin, Poland.
Kathleen M DarcyGynecologic Cancer Center of Excellence, Department of Gynecologic Surgery and Obstetrics, Uniformed Services University of the Health Sciences, Walter Reed National Military Medical Center, Bethesda, Maryland, USA.
Mona A El-BahrawyDepartment of Metabolism, Digestion and Reproduction, Imperial College London, Hammersmith Hospital, London, UK.
Esther ElishaevDepartment of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
Ramona ErberInstitute of Pathology, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, University Hospital Erlangen, Erlangen, Germany.
Rhonda FarrellPrince of Wales Private Hospital, Randwick, New South Wales, Australia.
Sian FeredayPeter MacCallum Cancer Centre, Melbourne, Victoria, Australia.ORCID 0000-0002-8559-8579
Anna FischerInstitute of Pathology and Neuropathology, Tuebingen University Hospital, Tuebingen, Germany.
María J GarcíaComputational Oncology Group, Structural Biology Programme, Spanish National Cancer Research Centre (CNIO), Madrid, Spain.
Simon A GaytherCenter for Bioinformatics and Functional Genomics and the Cedars Sinai Genomics Core, Cedars-Sinai Medical Center, Los Angeles, California, USA.
Aleksandra Gentry-MaharajMRC Clinical Trials Unit, Institute of Clinical Trials & Methodology, University College London, London, UK.
C Blake GilksDepartment of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, British Columbia, Canada.
AOCS GroupCentre for Cancer Research, The Westmead Institute for Medical Research, University of Sydney, Sydney, New South Wales, Australia.
Marcel GrubeDepartment of Women's Health, Tuebingen University Hospital, Tuebingen, Germany.
Paul R HarnettDiscipline of Obstetrics and Gynaecology, The University of Sydney, Sydney, New South Wales, Australia.
Shariska Petersen HarringtonDivision of Gynecologic Oncology, Department of Obstetrics and Gynecology, The University of Kansas Medical Center, Kansas City, Kansas, USA.
Philipp HarterDepartment of Gynecology and Gynecologic Oncology, Evangelische Kliniken Essen-Mitte (KEM), Essen, Germany.
Arndt HartmannInstitute of Pathology, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, University Hospital Erlangen, Erlangen, Germany.
Jonathan L HechtDepartment of Pathology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts, USA.
Sebastian HeikausCenter for Pathology, Evangelische Kliniken Essen-Mitte, Essen, Germany.
Alexander HeinDepartment of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, University Hospital Erlangen, Erlangen, Germany.
Florian HeitzDepartment of Gynecology and Gynecologic Oncology, Evangelische Kliniken Essen-Mitte (KEM), Essen, Germany.
Joy HendleyPeter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
Brenda Y HernandezUniversity of Hawaii Cancer Center, Honolulu, Hawaii, USA.
Susanna Hernando PoloMedical Oncology Service, Hospital Universitario Funcación Alcorcón, Alcorcón, Spain.
Sabine HeubleinDepartment of Obstetrics and Gynecology, University Hospital Heidelberg, Heidelberg, Germany.
Akira HirasawaDepartment of Clinical Genomic Medicine, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, Okayama, Japan.
Estrid HøgdallDepartment of Pathology, Herlev Hospital, University of Copenhagen, Copenhagen, Denmark.
Claus K HøgdallDepartment of Gynaecology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.
Hugo M HorlingsDivision of Molecular Pathology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
David G HuntsmanDepartment of Obstetrics and Gynecology, University of British Columbia, Vancouver, British Columbia, Canada.
Tomasz HuzarskiDepartment of Genetics and Pathology, International Hereditary Cancer Center, Pomeranian Medical University, Szczecin, Poland.
Andrea JewellDivision of Gynecologic Oncology, Department of Obstetrics and Gynecology, The University of Kansas Medical Center, Kansas City, Kansas, USA.
Mercedes Jimenez-LinanDepartment of Histopathology, Addenbrooke's Hospital, Cambridge, UK.
Michael E JonesDivision of Genetics and Epidemiology, The Institute of Cancer Research, London, UK.
Scott H KaufmannDivision of Oncology Research and Department of Molecular Pharmacology & Experimental Therapeutics, Mayo Clinic, Rochester, Minnesota, USA.
Catherine J KennedyCentre for Cancer Research, The Westmead Institute for Medical Research, University of Sydney, Sydney, New South Wales, Australia.ORCID 0000-0002-4465-5784
Dineo KhabeleDivision of Gynecologic Oncology, Department of Obstetrics and Gynecology, Washington University in St. Louis, St. Louis, Missouri, USA.
Felix K F KommossInstitute of Pathology, Heidelberg University Hospital, Heidelberg, Germany.
Roy F P M KruitwagenDepartment of Obstetrics and Gynecology, Maastricht University Medical Centre, Maastricht, The Netherlands.
Diether LambrechtsDepartment of Human Genetics, Laboratory for Translational Genetics, KU Leuven, Leuven, Belgium.
Nhu D LeCancer Control Research, BC Cancer Agency, Vancouver, British Columbia, Canada.
Marcin LenerInternational Hereditary Cancer Center, Department of Genetics and Pathology, Pomeranian Medical University in Szczecin, Szczecin, Poland.
Jenny LesterDavid Geffen School of Medicine, Department of Obstetrics and Gynecology, University of California at Los Angeles, Los Angeles, California, USA.
Yee LeungDivision of Obstetrics and Gynaecology, Faculty of Health and Medical Sciences, University of Western Australia, Crawley, Western Australia, Australia.
Anna LinderDepartment of Obstetrics and Gynecology, Inst of Clinical Science, Sahlgrenska Center for Cancer Research, University of Gothenburg, Gothenburg, Sweden.
Liselore LoverixDivision of Gynecologic Oncology, Department of Gynecology and Obstetrics, Leuven Cancer Institute, Leuven, Belgium.
Jan LubińskiDepartment of Genetics and Pathology, International Hereditary Cancer Center, Pomeranian Medical University, Szczecin, Poland.
Rashna MadanDepartment of Pathology and Laboratory Medicine, The University of Kansas Medical Center, Kansas City, Kansas, USA.
G Larry MaxwellInova Health System Women's Service Line, Falls Church, Virginia, USA.
Francesmary ModugnoDivision of Gynecologic Oncology, Department of Obstetrics, Gynecology and Reproductive Sciences, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
Susan L NeuhausenDepartment of Population Sciences, Beckman Research Institute of City of Hope, Duarte, California, USA.
Alexander OlawaiyeDivision of Gynecologic Oncology, Department of Obstetrics, Gynecology and Reproductive Sciences, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
Siel OlbrechtDivision of Gynecologic Oncology, Department of Gynecology and Obstetrics, Leuven Cancer Institute, Leuven, Belgium.
Sandra OrsulicDavid Geffen School of Medicine, Department of Obstetrics and Gynecology, University of California at Los Angeles, Los Angeles, California, USA.
José PalaciosDepartment of Pathology, Hospital Ramón y Cajal, Instituto Ramon y Cajal de Investigación Sanitaria (IRyCIS), CIBERONC, Universidad de Alcalá, Madrid, Spain.
Celeste Leigh PearceDepartment of Epidemiology, University of Michigan School of Public Health, Ann Arbor, Michigan, USA.
Malcolm C PikeDepartment of Epidemiology and Biostatistics, Memorial Sloan-Kettering Cancer Center, New York, New York, USA.
Carmel M QuinnThe Health Precincts Biobank, UNSW Biospecimen Services, Mark Wainwright Analytical Centre, University of NSW Sydney, Sydney, New South Wales, Australia.
Ganendra Raj MohanDepartment of Gynaecological Oncology, St John of God Subiaco Hospital, Subiaco, Western Australia, Australia.
Cristina Rodríguez-AntonaHereditary Endocrine Cancer Group, Spanish National Cancer Research Center (CNIO), Madrid, Spain.
Matthias RuebnerDepartment of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, University Hospital Erlangen, Erlangen, Germany.
Andy RyanMRC Clinical Trials Unit, Institute of Clinical Trials & Methodology, University College London, London, UK.
Stuart G SalfingerDepartment of Gynaecological Oncology, St John of God Subiaco Hospital, Subiaco, Western Australia, Australia.
Naoko SasamotoObstetrics and Gynecology Epidemiology Center, Department of Obstetrics and Gynecology, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA.ORCID 0000-0002-4526-2181
Joellen M SchildkrautDepartment of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, Georgia, USA.ORCID 0000-0002-0990-9339
Minouk J SchoemakerDivision of Genetics and Epidemiology, The Institute of Cancer Research, London, UK.
Mitul ShahDepartment of Oncology, Centre for Cancer Genetic Epidemiology, University of Cambridge, Cambridge, UK.
Raghwa SharmaTissue Pathology and Diagnostic Oncology, Westmead Hospital, Sydney, New South Wales, Australia.
Yurii B ShvetsovUniversity of Hawaii Cancer Center, Honolulu, Hawaii, USA.
Naveena SinghDepartment of Pathology, Barts Health National Health Service Trust, London, UK.
Gabe S SonkeDepartment of Medical Oncology, The Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands.
Linda SteeleDepartment of Population Sciences, Beckman Research Institute of City of Hope, Duarte, California, USA.
Colin J R StewartSchool for Women's and Infants' Health, University of Western Australia, Perth, Australia.
Karin SundfeldtDepartment of Obstetrics and Gynecology, Inst of Clinical Science, Sahlgrenska Center for Cancer Research, University of Gothenburg, Gothenburg, Sweden.
Anthony J SwerdlowDivision of Genetics and Epidemiology, The Institute of Cancer Research, London, UK.
Aline TalhoukDepartment of Obstetrics and Gynecology, University of British Columbia, Vancouver, British Columbia, Canada.ORCID 0000-0001-7760-410X
Adeline TanDivision of Obstetrics and Gynaecology, Faculty of Health and Medical Sciences, University of Western Australia, Crawley, Western Australia, Australia.
Sarah E TaylorDivision of Gynecologic Oncology, Department of Obstetrics, Gynecology and Reproductive Sciences, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
Kathryn L TerryObstetrics and Gynecology Epidemiology Center, Department of Obstetrics and Gynecology, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA.
Aleksandra TołoczkoDepartment of Genetics and Pathology, Pomeranian Medical University, Szczecin, Poland.
Nadia TraficantePeter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
Koen K Van de VijverDepartment of Pathology, Ghent University Hospital, Cancer Research Institute Ghent (CRIG), Ghent, Belgium.
Maaike A van der AaDepartment of Research, Netherlands Comprehensive Cancer Organization (IKNL), Utrecht, The Netherlands.
Toon Van GorpDivision of Gynecologic Oncology, Department of Gynecology and Obstetrics, Leuven Cancer Institute, Leuven, Belgium.
Els Van NieuwenhuysenDivision of Gynecologic Oncology, Department of Gynecology and Obstetrics, Leuven Cancer Institute, Leuven, Belgium.
Lilian van-WagensveldDepartment of Obstetrics and Gynecology, Maastricht University Medical Centre, Maastricht, The Netherlands.
Ignace VergoteDivision of Gynecologic Oncology, Department of Gynecology and Obstetrics, Leuven Cancer Institute, Leuven, Belgium.ORCID 0000-0002-7589-8981
Robert A VierkantDepartment of Quantitative Health Sciences, Division of Clinical Trials and Biostatistics, Mayo Clinic, Rochester, Minnesota, USA.
Chen WangDepartment of Quantitative Health Sciences, Division of Computational Biology, Mayo Clinic, Rochester, Minnesota, USA.
Lynne R WilkensUniversity of Hawaii Cancer Center, Honolulu, Hawaii, USA.
Stacey J WinhamDepartment of Quantitative Health Sciences, Division of Computational Biology, Mayo Clinic, Rochester, Minnesota, USA.
Anna H WuDepartment of Population Health and Public Health Sciences, Keck School of Medicine, University of Southern California Norris Comprehensive Cancer Center, Los Angeles, California, USA.
Javier BenitezCentre for Biomedical Network Research on Rare Diseases (CIBERER), Instituto de Salud Carlos III, Madrid, Spain.
Andrew BerchuckDepartment of Obstetrics and Gynecology, Division of Gynecologic Oncology, Duke University Medical Center, Durham, North Carolina, USA.
Francisco J Candido Dos ReisDepartment of Gynecology and Obstetrics, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, Brazil.
Anna DeFazioThe Daffodil Centre, The University of Sydney, A Joint Venture With Cancer Council NSW, Sydney, New South Wales, Australia.
Peter A FaschingDepartment of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, University Hospital Erlangen, Erlangen, Germany.
Ellen L GoodeDepartment of Quantitative Health Sciences, Division of Epidemiology, Mayo Clinic, Rochester, Minnesota, USA.
Marc T GoodmanCancer Prevention and Control Program, Cedars-Sinai Cancer, Cedars-Sinai Medical Center, Los Angeles, California, USA.
Jacek GronwaldDepartment of Genetics and Pathology, International Hereditary Cancer Center, Pomeranian Medical University, Szczecin, Poland.
Beth Y KarlanDavid Geffen School of Medicine, Department of Obstetrics and Gynecology, University of California at Los Angeles, Los Angeles, California, USA.
Stefan KommossDepartment of Women's Health, Tuebingen University Hospital, Tuebingen, Germany.
Usha MenonMRC Clinical Trials Unit, Institute of Clinical Trials & Methodology, University College London, London, UK.
Hans-Peter SinnInstitute of Pathology, Heidelberg University Hospital, Heidelberg, Germany.
Annette StaeblerInstitute of Pathology and Neuropathology, Tuebingen University Hospital, Tuebingen, Germany.
James D BrentonCancer Research UK Cambridge Institute, University of Cambridge, Cambridge, UK.
David D BowtellPeter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
Paul D P PharoahDepartment of Oncology, Centre for Cancer Genetic Epidemiology, University of Cambridge, Cambridge, UK.
Susan J RamusSchool of Clinical Medicine, UNSW Medicine and Health, University of NSW Sydney, Sydney, New South Wales, Australia.
Martin KöbelDepartment of Pathology and Laboratory Medicine, University of Calgary, Foothills Medical Center, Calgary, Alberta, Canada.ORCID 0000-0002-6615-2037
The University of Sydney · AUUniversity of Hawaiʻi at Mānoa · USUniversity of Pittsburgh · USUniversity of California, Los Angeles · USBrigham and Women's Hospital · USInstitute of Cancer Research · GBThe University of Melbourne · AUUniversity of British Columbia · CAUniversity of Calgary · CAUniversity of Southern California · USHeidelberg University · DESt John of God Subiaco Hospital · AUUniversity of Cambridge · GBBC Cancer Agency · CACedars-Sinai Medical Center · USHelios Dr. Horst Schmidt Kliniken Wiesbaden · DEInova Health System · USMaastricht University Medical Centre · NLMRC Clinical Trials Unit at UCL · GBUniversitätsklinikum Erlangen · DE

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4M
USC/NORRIS COMPREHENSIVE CANCER CENTER (CORE) SUPPORTP30CA014089 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI MYLES G COCKBURN · 1985 to 2026
$181.4M
VECTOR CORE FACILITYP30CA047904 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI JOHN C. BYRD · 1988 to 2026
$158.0M
Women's Cancer ProgramP30CA015083 · NCI · MAYO CLINIC ROCHESTER · PI AKHILESH PANDEY · 1985 to 2026
$151.3M
UCLA Clinical and Translational Science InstituteUL1TR000124 · NCATS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI DUBINETT, STEVEN M. · 2012 to 2015
$57.0M
University of Hawaii Cancer Center CCSGP30CA071789 · NCI · UNIVERSITY OF HAWAII AT MANOA · PI GERTRAUD MASKARINEC · 1996 to 2026
$56.2M
Use of microfluidic tumor cultures to enable clinical trials of therapies for ovarian cancerP50CA136393 · NCI · MAYO CLINIC ROCHESTER · PI ELLEN L. GOODE · 2009 to 2026
$37.0M
WITHIN SUBJ VARIABILITY IN MEASUREMENTS DRUG METABOL ENZYMES IN HLTY SUBJM01RR000056 · NCRR · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI LEVINE, ARTHUR S · 1985 to 2006
$29.2M
Relating Molecular Subgroups of Endometriosis-Associated Ovarian Cancers to Survival and RiskR01CA248288 · NCI · MAYO CLINIC ROCHESTER · PI Stacey J Winham · 2021 to 2026
$4.8M
Sequencing Familial Lung CancerR01CA243483 · NCI · UNIVERSITY OF NEW MEXICO HEALTH SCIS CTR · PI Christopher I. Amos, DIPTASRI M MANDAL · 2023 to 2026
$4.2M
Identifying Prognostic Markers and Therapeutic Targets for Serous Ovarian CancerR01CA172404 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI RAMUS, SUSAN J · 2013 to 2017
$2.9M
Inflammation and Ovarian CancerR01CA095023 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI BUNKER, CLAREANN H. · 2003 to 2008
$2.7M
Cancer Research UK 15601Cancer Research UK 22905Medical Research Council MC_UU_00004/01NCATS NIH HHS UL1 TR000124NCI NIH HHS K07 CA080668NCI NIH HHS N01 CA015083NCI NIH HHS P30 CA008748NCI NIH HHS P30 CA014089NCI NIH HHS P30 CA015083NCI NIH HHS P30 CA047904NCI NIH HHS P30 CA071789NCI NIH HHS P50 CA136393NCI NIH HHS R01 CA095023NCI NIH HHS R01 CA122443NCI NIH HHS R01 CA160669NCI NIH HHS R01 CA172404NCI NIH HHS R01CA172404NCI NIH HHS R01 CA243483NCI NIH HHS R01 CA243511NCI NIH HHS R01 CA248288NCI NIH HHS R21 CA210210NCI NIH HHS U01 CA243483NCRR NIH HHS M01 RR000056
6 · The paper itself

Abstract

backgroundCyclin E1 (CCNE1) is a potential predictive marker and therapeutic target in tubo-ovarian high-grade serous carcinoma (HGSC). Smaller studies have revealed unfavorable associations for CCNE1 amplification and CCNE1 overexpression with survival, but to date no large-scale, histotype-specific validation has been performed. The hypothesis was that high-level amplification of CCNE1 and CCNE1 overexpression, as well as a combination of the two, are linked to shorter overall survival in HGSC.

methodsWithin the Ovarian Tumor Tissue Analysis consortium, amplification status and protein level in 3029 HGSC cases and mRNA expression in 2419 samples were investigated.

resultsHigh-level amplification (>8 copies by chromogenic in situ hybridization) was found in 8.6% of HGSC and overexpression (>60% with at least 5% demonstrating strong intensity by immunohistochemistry) was found in 22.4%. CCNE1 high-level amplification and overexpression both were linked to shorter overall survival in multivariate survival analysis adjusted for age and stage, with hazard stratification by study (hazard ratio [HR], 1.26; 95% CI, 1.08-1.47, p = .034, and HR, 1.18; 95% CI, 1.05-1.32, p = .015, respectively). This was also true for cases with combined high-level amplification/overexpression (HR, 1.26; 95% CI, 1.09-1.47, p = .033). CCNE1 mRNA expression was not associated with overall survival (HR, 1.00 per 1-SD increase; 95% CI, 0.94-1.06; p = .58). CCNE1 high-level amplification is mutually exclusive with the presence of germline BRCA1/2 pathogenic variants and shows an inverse association to RB1 loss.

conclusionThis study provides large-scale validation that CCNE1 high-level amplification is associated with shorter survival, supporting its utility as a prognostic biomarker in HGSC.

Indexed as

CarcinomaCystadenocarcinoma, SerousOvarian NeoplasmsCyclin EFemaleHumansOncogene ProteinsRNA, MessengerTranscription FactorsCCNE1 protein, humanCyclin EOncogene ProteinsRNA, MessengerTranscription FactorsCCNE1 amplificationcyclin E1 expressionhigh-grade serous carcinomaovarian cancerprognosis

Identifiers

PMID36572991
PMCPMC10107112
OpenAlexW4312210137

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.